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ABSTRACT
PROSTACYCLIN AND THROMBOXANE A IN THE
2
ATHEROSCLEROSIS SUSCEPTIBLE AND SUPER
SUSCEPTIBLE WHITE GARNEAU PIGEON
Janet Melvin Royer
Morehead S t a t e ~ s i
Director of Thesis:
Two strains of the White C

pigeon, the

atherosclerosis susceptible random bred White Garneau·
(RBWC) and the super susceptible White Garneau II.
(WC-II), were used to investigate the opposing roles
of prostacyclin (PGI 2 ) and thromboxane A (TXA ) in·
2
2
the development of atherosclerosis. Since TXA 2 is
produced by platelets, platelet counts were determined
to rule out the influence of platelet number on the
production of TXA 2 . There ~as no statistical difference in the means of the two strains, therefore any
differences in TXA~,. levels were true differences.
Plasma and aorta samples were tested for their levels
of 6-keto-prostaglandin F 1 a (6-keto-PGF 1 a), t~:~stable
metabolite of PGI 2 , by radioimmunoassay (RIA>°.t ;·simultaneously plasma and platelet rich plasma (PRP)c. samples
were evaluated by RIA for their levels of thromboxane
B (TXB 2 ), the stable metabolite of TXA 2 . It was
2
found that the more susceptible WC-II pigeon generated

iii

-

more TXB

than the RBWC. The WC-II also produced a
2
significantly higher amount of 6-keto-PGF 1 a when given
arachidonic acid stimulation.

This would indicate that

the super susceptible WC-II exhibits a defense
mechanism to the progression of atherosclerosis by the
increased ability to synthesize PGI 2 in response to
increased levels of TXA 2 .
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INTRODUCTION
Atherosclerosis is a principle cause of heart
disease.

Recently Hopkins and Williams (1981) have

compiled 246 factors associated with atherosclerosis
and coronary heart disease, and grouped these into four
categories:

the initiators which unde=ine the integ-

rity of the arterial endothelium, the promoters which
promote the buildup 0£ cholesterol, the potentiators
which.increase the likelihood of thrombi and potentiates the previous two, and the precip'itators which induce acute ischemic events or arrhythmia and precipitate
a heart attack.
Due to the prevalence of atherosclerosis and
heart disease, a great deal of research has been conducted on the factors that constitute these four categories in the United States and abroad.
This study deals with the roles of prostacyclin
and thromboxane A2 in the susceptibility to atherosclerosis. The White Garneau pigeon was the animal model
selected to use in this investigation.

The hypothesis

for this study will be developed throughout the review
of the literature, and stated along with the objectives
and means to achieve these objectives at the end of
the introduction.

1

2

Atherosclerosis seems to be initiated by
factors that alter the endothelial cell lining of vascular tissues, such as hyperlipidemia, certain metabolites, infectious agents or immunological injury,
thus exposing the subendothelial collagen layer (Ross,
Glomset, and Harker, 1977).

When exposed ·to the sub-

endothelium, blood platelets adhere, then aggregate
and release the contents of their granules (Ross and
Glomset, 1976).

This is followed by smooth muscle

cell (SMC) proliferation, and the synthesis and deposition of collagen fibrils, elastic fibers, proteoglycans, and lipids (Harker, Ross, Slichter, and
Scott, 1976).

These events ultimately lead to the

formation of a primary lesion.

The primary lesion

formation may be prevented by inhibition of platelet
consumption (Harker, et al., 1976).
If the source or sources of intimal injury
persists then additional SMC proliferation will occur
along with added connective tissue and lipid deposition
(Ross and Glomset, 1976), leading to the atherosclerotic
plaque and narrowing of the vascular internal diameter.
The interaction between the damaged vascular
wall and platelets results in the release from the
platelets of the prostaglandin derivative, thromboxane

3

A2 (TXA 2 ) (Gryglewski, Bunting, Moncada, Flower, and
Vane, 1976). The Gryglewski and Moncada research teams
proposed that a critical balance exists in the formation
of thrombi between the TXA2 formed by the platelets and
a substance initially called prostaglandin X (prostacyclin) produced by the vascular walls from the
endoperoxides, prostaglandins G2 and H . These endo2
peroxides may be produced by the stimulation of vasoconstriction, chemical irritation or injury to the
vascular tissue, or the endoperoxides may be supplied
by the platelets.

The prostacyclin (PGI 2 ) would act
to prevent platelet aggregation in the vicinity of the

affected vascular segment (Gryglewski, et al., 1976)
as shown in Figure 1.
It was later hypothesized by Gryglewski (1980)
that the beginning of atherosclerosis is causally
associated with a localized increase in lipid peroxides,
which inhibit prostacyclin synthetase, since these
lipid peroxides have been found in atherosclerotic
arteries but absent in healthy arteries.

It was further

postulated by Gryglewski (1980) that arterial thrombi
may be the result of the inability of the endothelial
tissue to generate enough prostacyclin.

This would

allow platelets to adhere and release TXA 2 , followed by

4
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Balance between PGiz and TXAz as described
by Gryglewski (1976).
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platelet aggregation and vasoconstriction as a result
of the inhibition of the PGI 2 synthetase enzyme by
lipid peroxides, endothelial detachment, or polymerizing fibrin preventing the interaction between
platelets and endothelial cells.
Prostacyclin, derived from arachidonic acid,
is formed from endoperoxides by arterial microsomes,
and is a potent inhibitor of platelet aggregation and
a strong vasodilator.

It has a short half-life and is

rapidly converted to the stable biologically inactive
prostaglandin (PG) product 6-keto-PGF a (Gryglewski,
1
et al., 1976; Bunting, Gryglewski, Moncada, and Vane,
1976; Gryglewski, 1980).
Various chemical compounds have been found to
stimulate or inhibit the production of PGI . The
2
synthesis of PGI 2 is stimulated by the administration
of estradiol and triidothyronine, but is inhibited
by the administration of testosterone (Nakao, Chang,
Hurota, and Orimo, 1981).

Furthermore, aortas from

animal models with vitamin E deficiency produced less
PGI , and TXA 2 production by the platelets was
2
increased in these animals upon stimulation by
collagen (Karpen, Merola, Trewyn, Co=well, and
Panganamola, 1981).

6

Thromboxane Az has a half-life of about thirtyfive seconds in aqueous solution and is rapidly converted to the stable biologically inactive thromboxane
Bz (TXBz) (Nelson, Kelly, Schneider, 1977).

There is

a high rate of conversion of endoperoxides to TXA

by
2
the microsomal fraction of platelets and lung tissue.

Thromboxane is a potent platelet aggregator as well
as a vasoconstrictor (Hamberg, Svensson, and
Samuelsson, 1975; Samuelsson, Granstrom, Green,
Hamberg, and Hammerstrom, 1975; Samuelsson, Goldyne,
Granstrom, Hamberg, Hammerstrom, and Malmsten, 1978).
Both PGI 2 and TXA2 are synthesized from the
same endoperoxides. Prostaglandin G2 (PGG 2 ) and
prostaglandin H2 (PGH 2 ) are synthesized from the 20carbon fatty acid, arachidonic acid, by the cyclooxygenase enzyme system.

The cyclo-oxygenase can be

inhibited by aspirin and indomethacin (Gryglewski, et
al, 1976).

The endoperoxides are then converted to

PGI

or TXA by prostacyclin synthetase and thrombcxane
2
2
synthetase respectively (Samuelsson, et al., 1975;·

Samuelsson, et al., 1978; Dusting, Moncada, and Vane,
1979; Gryglewski, 1980) as outlined in Figure 2.
Moncada and Vane (1977) proposed that the endoperoxides generated by platelets are utilized by the

7
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vessel enzymes to make PGI 2 which prevents platelets
from adhering to normal vessel walls. In their experiment, arterial rings perfused with platelet rich plasma
(PRP) g~µerated PGI . Arterial rings pretreated with
2
indomethacin, a cyclo-oxygenase inhibitor, and then
perfused with PRP produced PGI 2 . They concluded that
the cells of the vascular wall were able to utilize the
platelet endoperoxides for the production of the PGI 2 .
Subsequently, any inhibition in the ability to synthesize PGI

would remove the "inert" or repellent effect
2
of this· prostaglandin.
In the same year it was demonstrated, by
Samuelsson (1977) from a patient suffering from a
deficiency of platelet cyclo-oxygenase, that no platelet aggregation would occur, thus indicating the need
for available endoperoxides to synthesize TXA 2 .
Earlier it was pointed out by Ellis, Oelz,
Roberts, Payne, Sweetman, Niess, and Oates (.1976) that
the TXA

2

released in the area of the damaged endo-

thelium causes arterial constriction and therefore
cardiac complications simply by being a vasoconstrictor.
Although the hypotheses by Gryglewski, et al.,
(1976) and Moncada and Vane (1977) on the generation
of PGI

2

have been widely accepted, variations of these

9

basic proposals exist.

One such proposal states that

the blood vessels can "steal" the platelet endoperoxides, in particular the PGH 2 , but only when there is
endothelial damage, not as a normal coursa of events
in platelet repulsion (Sivakoff, Pure, Hsueh, and
Needleman, 1979).

In addition, the atherosclerotic

plaque decreases the vessel's ability to synthesize
PGI 2 and thereby reduces its defense capabilities.
Hamstra, Haddeman, and Don (1979) stated that
vessels treated with indomethacin should generate PGI

2
when supplied with endoperoxides as previously reported.
However, upon repeating the experiment by Sivakoff,
et al., they found that there was no synthesis of PGI .
2
They explained this incongruency by proposing that
indomethacin binds reversibly to the cyclo-oxygenase
enzyme and the vessels were then able to utilize their
own prostaglandin endoperoxides after a greater period
of time.
More recently it has been proposed that the
platelet derived growth factor (PDGF) released from the
platelet granules upon aggregation stimulates the
production of PGI 2 (Coughlin, Moskowitz, Zetter,
Antoniades, and Levine, 1980). Paralleling this finding
was another from a study of platelets that had undergone

10

freeze etching.

This showed that the lack of platelet

proturberances caused by PGI 2 brought about a
stabilizing effect, thereby regulating the release of
PDGF from the platelets and thus controlling the proliferation of SMC (Weber, Bianciardi, Toti, and
Sinzinger, 1981).

Since the proliferation of SMC tis-

sue accompanies the development of the atherosclerotic
lesion, these two studies suggest a feedback mechanism.
In yet another study it was demonstrated that
PRP treated with aspirin, a cyclo-oxygenase inhibitor,
could stimulate aortic strips to generate 6-keto-PGF 1 a,
the stable metabolite of PGI 2 . So some factor other
than platelet endoperoxides was responsible for its
synthesis of 6-keto-PGF a. These may be such factors
1
as PDGF and the mechanical impact of the platelets on
the endothelial cells (Galli, Petroni, Socini, Agradi,
Colombo, Folco, and Tremoli, 1981).

This idea of

mechanical impact was expanded by Korbut, Boyd, and
Eling (1982) when they proposed that it was the action
of the platelet to disturb the vascular wall cell
membrane, which in turn stimulates phospholipase to
cleave arachidonic acid from the vascular cell membrane
bound phospholipids.

The free arachidonic acid is then

converted by the vascular cell microsomes to PGI 2 .
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Whatever the source or sources of the generation
of prostacyclin, it has been shown experimentally that
PGI

and TXA piay opposing roles in atherogenesis.
2
2
Da-ca collected on various mammalian· species indicate
that species more susceptible to atherosclerosis produce smaller amounts of PGI /mg tissue wet weight/minute
2
than less susceptible species (Sinzinger, Clopath,
Silberbaurer, and Winter, 1980).
In the atherosclerotic rabbit the platelets
were noted to produce two times more TXB 2 than platelets
from controls within a five minute incubation with
arachidonic acid.

In addition, the ability of the PGI 2
to inhibit the formation of TXB 2 in intact platelets

was more pronounced in atherosclerotic rabbits
(Dembrinska-Kiec, Ricker, and Schonhofer, 1979), showing
an increased sensitivity as part of a defense mechanism.
It was also evidenced that the conversion of arachidonic
acid to 6-keto-PGF a in the atherosclerotic rabbit
1
heart tissue was suppressed by as much as 40% of the
controls.

The aortic rings of these animals synthesized

less prostacyclin than the controls (Dembinska-Kiec,
Gryglewski, Zmuda, and Gryglewski, 1977).

These experi-

ments reflect the hypotheses, stated in various forms
earlier that the inability to generate adequate amounts

12
.

of PGI

leads to the greater synthesis of TXA2 and
2
ultimately to hemostatic irregularities.
Another animal that has been used as a model in
the study of atherosclerosis is the pigeon.

Certain

breeds of the pigeon tend to be resistant to atherosclerosis while others are susceptible to the spontaneous development of the disease.

The Show Racer

pigeon is resistant while the White Garneau will
develop spontaneous atherosclerosis (Lofland and
Clarkson, 1960).
Nearly 100% of the White Garneau pigeons have
macroscopic aortic lesions by the age of three years
with severity correlated to age, and these lesions are
more numerous and severe in the lower half of the
thoracic aorta where the celiac artery emerges.

These

lesions are typically made up of cholesterol, other
lipids, collagen, and smooth muscle cells (Prichard,
Clarkson, Goodman, and Lofland, 1964).

Between nine

to twelve months of age, termed the critical period of
sterol accumulation, there is a significant increase
in the total sterol content of the White Garneau aorta
as well as a doubling of the level of esterified
cholesterol that is not detected in the Show Racer
(Subbiah, Unni, Kottke, Carlo, and Dinh, 1976).

.
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There is also microscopic evidence of plasma
membrane ruffling and extensive endothelial desquamation
occurring in the White Carneau prior to the critical
period, becoming more pronounced with age.

These sites

are usually coupled to platelet aggregates (Lewis and
Kottke, 1977).
When compared to mammals the pigeon production
of PGI

is low, but interesting in that the production
2
of 6-keto-PGF a is significantly higher in the athero1
sclerosis susceptible White Carneau than in the resistant Show Racer, when aorta homogenates were stimulated

with arachidonic acid (Subbiah, Schweiger, Deitmeyer,
Gallon, and Sinzinger, 1980).

This finding is somewhat

in opposition to that reported to occur in mammalian
species; however, an explanation would be conjectural
since TXA

was not determined by Subbiah's study.
2
The White Carneau pigeon is an excellent choice

for an animal model in the study of atherosclerosis,
since it, like the human, develops spontaneous atherosclerosis.

Interpreting the def·inition of atherosclero-

sis supplied by the World Health Organization, Prichard,
et al., (1964) concluded that only the human, the pigeon,
and a few long-lived birds maintained at zoos developed
lesions that satisfied the requirements of intimal

14

changes consisting of the accumulation of lipids, carbohydrates, blood and blood products, fibrous tissue, and
calcium associated with medial changes.
The White Garneau pigeon may also exhibit an
intricate defense mechanism in response to atherogenesis.

Thus the roles of PGI

and TXA may be examined
2
2
in this relation to the differences in susceptibility

of pigeons.
The purpose of this study was to test the
hypothesis that in atherosclerosis there is a correlation of decreased synthesis of PGI

in response to the
2
The objectives of this

increased production of TXA 2 .
study were to determine the differences; if any, in the
unstimulated and arachidonic acid stimulated levels of
PGI 2 and TXA 2 in atherosclerosis susceptible and super
susceptible White Garneau pigeons. To achieve these
objectives, pigeons of both strains of the White
Garneau were purchased from the Bowman Gray Medical
School at Wake Forest University, Winston-Salem, North
Carolina.

Radioimmunoassay was used to determine PGI 2
Plasma samples from both strains were

and TXA 2 .
examined for platelet count to eliminate the influence

of platelet number on the production of TXA . Platelet
2
rich plasma and aorta samples of both strains, with and
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without arachidonic acid stimulation were tested for
levels and TXA

and PGI respectively. Therefore, the
2
2
analysis of these assays would indicate differences in
the abiltty to synthesize these two compounds, TXA2
and PGI , inherent to the strain.
2

MATERIALS AND METHODS
Animal Sel·ection and Care
Fifteen atherosclerosis susceptible random bred
White Garneau (RBWC) pigeons and fifteen super susceptible Wh~te Garneau-II (WC-II) pigeons were obtained
from the Bowman Gray Medical School at Wake Forest
University (Winston-Salem, North Carolina) .

The·

pigeons ranged in age from one to fifteen months and
included males and females.

Two of the WC-II expired

within two weeks of arrival, all others were housed in
wire cages in groups or separately according to their
compatibility in an animal room with approximately ten
hours of darkness and fourteen hours of light simulating natural conditions.

All birds were maintained,

ad libitum, on cholesterol free diets of Purina Pigeon
Chow (Ralston-Purina Co.) consisting of approximately
40 grams of food daily with adequate fresh water.
Collection and Handling of Samples
When collecting blood samples, the birds were
held firmly on their sides, one wing extended and held
in place, and the area of puncture was cleaned with an
alcohol swab and dried with sterile cotton before withdrawing sample.

All blood samples were collected from
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the alar vein of the wing using 10 cc syringes with
22 gauge hypodermic needles to prevent clotting in the
needle and unnecessary hemolysis of sample.

Samples

of 1 to 2 ml were usually collected no more than one
time per week to prevent undue stress on the birds.
After collection, the blood was immediately transferred
to silicon glass test tubes containing 4.4 mM EDTA,
to obtain plasma to be used in the platelet count and
in the formation of platelet rich plasma.

Samples

used for the radioimmunoassay of 6-keto-PGF 1 a and TXB 2
were immediately transferred after collection to silicon glass tubes containing 4.4 mM EDTA and indomethacin
in the concentration of 1 µg/ml of blood.

The indo-

methacin solution was prepared by adding 0.0264 grams
of Tris HCl and 0.0403 grams of Tris base to 5.0 ml of
distilled water at pH 8.4, then 1 mg of indomethacin
was added.

Next 0.0635 grams of Tris HCl and 0.0118

grams of Tris base were mixed in 100 ml of dH 2 0, and
95 ml of this solution at pH 7.5 were added to the 5 ml
of the indomethacin solution.

For each ml of blood

collected 0.1 ml of this final solution was used.
Blood samples to be used for the platelet count
were processed within thirty minutes after collecting.
Samples for the determination of levels of
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6-keto-PGF 1 ~ and TXB 2 were placed on ice until
processed.
Plasma was obtained by centrifuging the blood
at 1500 rpm for five minutes in a clinical centrifuge
and immediately removing the plasma from the packed
cells.
Aorta samples were collected by sacrificing
the bird via injection of excess Nembutal (Abbott Co.)
and then placing the head of the bird in a closed
container saturated with diethyl ether.

After this, a

10 to 15 mm section of the aorta at the celiac origin
was removed and placed on ice.

These samples were

processed within minutes of removal.
Platelet Count
The Rees and Ecker method was employed for the
platelet count.

The Rees and Ecker solution was pre-

pared by adding 1.0 gram of brilliant cresyl blue (Sigma
Chemical Co.), 3.8 grams of sodium citrate, and 0.2 ml
of 40% formaldehyde in a final volume of 100 ml.

This

solution was prepared fresh and filtered before each
use.
The platelet count was determined from the
plasma which was removed from the packed cells with a
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Pasteur pipet, and placed in labelled disposable test
tubes.

Using the red blood cell pipet supplied with

the hemocytometer (Spencer Optical Co.), the plasma
was drawn to the 0.5 mark.

The Rees and Ecker solution-

was drawn to the 101 mark and the pipet gently shaken
for three minutes.

The first five drops were dis-

charged from the pipet, the chambers on the hemocytometer charged, and the hemocytometer placed in a
covered petri dish containing moist cotton balls for
five minutes to allow the platelets to settle while
preventing excessive evaporation.

The hemocytometer

was then placed on the stage of a microscope and
observed at a magnification of 400.

The platelets,

appearing as small glistening bodies, were counted in
the five sections used for the red cell count.

This

number was then multiplied by 200 (dilution correction
factor) and then by 50 (volume correction factor) to
yield the total number of platelets per mm 3 of plasma
(Seiverd, 1972).

All samples were counted in duplicate

and the average was recorded.
Extraction of Samples
All samples for radioimmunoassay (RIA) were subjected to extraction procedures to remove proteinaceous
materials that might interfere with the assays (Green,
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Hamberg, Samuelsson, and Frolich, 1978).

The extrac-

tion procedures presented are·modifications of those
used by Yamamoto, 0gino, 0hki, and Yoshimoto (1977);
Dembinska-Kiec, et al., (1977); and Granstrom and
Kindahl (1978).
Samples were placed in glassware siliconized
with a 5% solution of dimethyldichlorosilane, or in
polypropylene test tubes.

Disposable polypropylene

pipet tips were also used in transferring the samples
since prostaglandins adhere to unsiliconized glass
surfaces.
To test for circulating levels of 6-keto-PGF a
1
and TXB 2 by RIA, 0.5 ml aliquots of plasma were removed
from the packed cells and placed in clean, siliconized
test tubes.

The sample was chilled on ice, acidified

to pH 3.0 with 1 N HCl, and extracted in five volumes
of ethyl acetate.

This solution was mixed with a

Vortex mixer, allowed to separate, and the organic
layer removed to the flask of a roto-evaporater.

The

ethyl acetate was then evaporated rapidly under reduced
pressure and constant temperature by immersing the
evaporating chamber in a water bath.

The residue was

then redispersed in 1 ml of the RIA buffer (New England
Nuclear) consisting of 50 mM phosphate buffer at pH 6.8
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with 0.1% gelatin and 0.01% thimersol as preservatives.
The solution was transferred to a polypropylene tube,
capped, and frozen until time of assay.
Platelet rich plasma samples were extracted by
using two 0.25 ml aliquots of plasma from each pigeon
tested, and centrifuging these tubes at 3000 rpm for
fifteen minutes to form platelet pellets.
was removed from these pellets.

Excess plasma

One ml of phosphate

buffered saline, pH 7.4, with 5.5 mM glucose was added
to one tube.

Then one ml of the phosphate buffered

saline with arachidionic acid (Sigma Chemical Co.) in
the concentration of 2.5 µg/ml was added to the second
tube.

These two samples were incubated for three min-

utes at room temperature, and a platelet count was
performed so that the TXB 2 levels could be expressed as
picograms per 10 8 platelets. The incubation period was
terminated by chilling and acidifying to pH 3.0 with
1 N HCl.

The samples were then extracted with five

volumes of ethyl acetate and processed as described for
the plasma sample.
After sacrificing, a section of aorta was
removed from each bird, immediately placed on ice, and
cut into two pieces of approximately equal size of about
5 to 8 mm in length.

Excess adipose tissue was removed
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from the pieces, then they were rinsed in phosphate
buffered saline containing 5.5 mM glucose, blotted dry,
and weighted.

One ring was added to a solution of 15 mM

Tris HCl, pH 7.4, containing 140 mM NaCl and 5.5 mM
glucose in the amount of 1 ml of solution per 20 mg
tissue (wet weight).

The second ring was placed in this

solution containing 2.5 µg/ml arachidionic acid in the
amount of 1 ml of solution per 20 mg tissue (wet weight).
The rings were incubated for five minutes and the incubation was terminated by chilling and acidifying to pH
3.0 with 1 N HCl.

These solutions were extracted with

five volumes of ethyl acetate and treated as described
for the plasma sample.
The RIA tracer solutions of tritiated
6-keto-PFG 1 a and TXB 2 were also extracted according to
the procedure for plasma to determine the percent
recovery of this method.
Radioiinmilhoassay for 6-keto-PGF 1·a and TXB 2
Assays for the level of 6-keto-PGF 1 a in the
plasma and aorta samples were carried out simultaneously
with assays for the level of TXB 2 in the plasma and PRP,
according to the specifications of the producers of the
RIA materials (New England Nuclear).

Samples were
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pipetted using a micropipettor with polypropylene disposable tips and processed in polypropylene tubes.
The RIA assay buffer (see Table 1) was added to
the appropriate tubes.

To these, standard, control, or

sample were added 1 followed by tracer and mixed.

The

tracer solution was composed of 1 µCi of tritated prostaglandin in 50 mM phosphate buffer at pH 6.8.

Then

the antiserum, produced by New England Nuclear in rabbits against a bovine serum albumin conjugate of the
prostaglandin, was added, mixed, and incubated for
sixteen hours at 4° C.
After the incubation period, 500 µl of charcoal
suspension was added to all tubes except the total count
tubes and incubated for 15 minutes at 4° C.

Only eight

samples were processed at one time to prevent exceeding
the maximum time of thirty minutes allowed, to avoid
excessive stripping of bound prostaglandin.

After the

fifteen minute period, these tubes were centrifuged at
l000Xg for ten minutes and decanted into scintillation
vials.

Five ml of scintillation cocktail (Atomlight,

New England Nuclear), used to absorb the excitation
energy from the beta decay, was added to each vial.
The vials were counted in a scintillation counter
(Packard model 300C).

Tube No.

Buffer

Total Counts

1-2

900

100

Blank

3-4

400

100

"O" Standard

5-6

300

100

100

7-18

200

100

100

Human Plasma Control
(0 ng/ml)

19-20

200

100

100

100

Human Plasma Control
(1 ng/ml)

21-22

200

100

100

100

200

100

100

100

Standards

Samples
Table 1.

23,24 etc.

Standard

Samples

100

Tracer

Antibody

Assay protocol for the RIA of 6-keto-PGF 1 q with all volumes expressed
in microliters (New England Nuclear, 1980).
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Determination of Values from Scintillation Counts
Using the counts per minute (cpm) obtained from
the counter, the disintegrations per minute (dpm) were
calculated by adjusting.for the efficiency of the system.

The efficiency is a function of the quinching

factor derived from the amount of light energy absorbed
by non-light producing substances such as the sample.
Therefore, the cpm divided by the efficiency of the
system yields the dpm.

The dpm is then used to deter-

mine the picogram yield of the standards, controls,
and samples as shown in Figure 3.

1.

Average net count= average standard or sample count minus average
blank count.

2.

% Bound=

3.

Normalized % Bound (%B/B 0 ) = % B of standard "or s·ample
% B of zero standard

Figure 3.

average net count
average net of total count tubes
X

100

Calculations for the determination of picogram values in
standards, controls, and samples (New England Nuclear, 1980).

N
cr,

RESULTS
To determine that any differences detected in
the levels of thromboxane in the two strains were true
differences in the rate of synthesis and pot because of
elevated platelet number, a platelet count was performed.
Ten pigeons of each strain were randomly selected.

The

average count for each bird is summarized in Table 2.
The RBWC had a mean count of 522,000/mm3 of plasma with
a standard deviation (S-) of 1.137 x 10 5 while the WC-II
.

X

had a mean count of 524,000/mm3 ,

Sx = 0.901 x 10 5 .

Using

the analysis of variance (ANOVA) statistical test, these
means were not found to be significantly different.
The next parameter of study was the RIA for
6-keto-PGF 1 ~, the stable metabolite of PGI 2 , in plasma
and aorta samples, and the RIA for TXB 2 , the stable
metabolite of TXA 2 , in plasma and PRP samples. Four
atherosclerosis susceptible RBWC and four super susceptible WC-II pigeons were selected to be tested for
these substances throughout the investigation.

These

pigeons were selected by age, ranging from nine to
nineteen months, to coincide with the critical period
of sterol accumulation.
The calculated normalized percent bound values
of the standards, expressed on three cycle semi-
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PLATELET COUNT
RBWC

WC-II

Age
(months)

Platelet Count/mm 3

Age
(months)

Platelet Count/mm 3

16

460,000

29

490,000

11

600,000

19

520,000

11

710,000

17

400,000

8

430,000

9

410,000

8

460,000

8

640,000

8

333,000

7

590,000

8

520,000

6

430,000

8

620,000

5

540,000

7

470,000

5

580,000

6

620,000

5

640,000

Table 2.

Platelet counts for the random Bred White Carneau (RBWC) and the
White Carneau-II (WC-II) pigeons. (RBWC- X = 522,000, S- = 1.137 x
5
.
5
X
10 ; WC-II- X = 524,000, S; = 0.901 x 10 ).
N
00
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logarithmic graph paper illustrating standardization
curves for 6-keto-PFG1 a and TXB 2 , are indicated on
Graphs 1 and 2. It should be noted that all values
expressed for the _RIA are not in vivo levels, but are
indicative of these levels and certainly may be used
as a basis of comparison between these two strains of
the White Garneau pigeon.
The plasma was tested to become acquainted with
what may be considered circulating levels of prostacyclin and thromboxane A2 as reflected by their metabolites, 6-keto-PGF 1 a and TXB 2 respectively. These
values, shown in Table 3, are expressed in picograms
per ml of extracted fluid.
The mean plasma levels of 6-keto-PGF a for the
1
RBWC (X = 36.00, S;; = 3.74) and for the WC-II (X =
45.75, S;; = 12.01) showed no statistically significant
difference using the ANOVA, but did indicate a tendency
for the WC-II to have more 6-keto-PGF 1 a in circulation
(F = 2.40, p = 0.172). The mean plasma levels of TXB 2
were not analyzed due to the extremely high values of
two of the WC-II pigeons.

Even though these results

were probably due to experimental error, they most
likely reflect elevated levels in the super susceptible
WC-II.
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Age
(months)

6-keto-'PGF 1 a
(pg/ml)

TXB 2
(pg/ml)

12

31

9

17

36

25

12

37

17

9

40

20

18

62

310

19

44

280

10

44

12

9

33

22

RBWC

WC-II

Table 3.

Plasma levels of 6-keto-PGF 1 a and TXB 2
expressed in picograms per ml extraction
fluid of the random bred White Garneau
(RBWC) and the White Garneau-II (WC-II).
(RBWC- X = 36.00, S-X = 3.74; WC-II- X =
45.75, S; = 12.01 for 6-keto-PGF 1 a).
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The levels of TXB 2 generated by the PRP of the
two strains were examined with and without arachidonic
acid stimulation.

These values, shown in Table 4, are
expressed in picograms per 10 8 platelets. The TXB
2
level of the PRP without arachidonic acid stimulation
was significantly higher in the WC-II (X = 19.5, Sx =
19.9) than in the RBWC (X = 5.3, Sx = 1.8), F = 7.52,
p = 0.05.

The TXB 2· level of the PRP with stimulation
showed a tendency to be higher in the WC-II as well,
(WC-II-

X.= 66.25, Sx = 67.54; RBWC- X = 14.32, Sx =

6.8) with F = 2.34, p = 0.17 .
.Analyzation of the aorta samples, shown in
Table 5 as picograms per mg of aorta wet weight, indicated no difference in the amount of 6-keto-PGF 1 a
between the RBWC (X = 5.687, S-X = 2.27) and the WC-II

(X = 8.32, Sx = 4.75) without arachidonic acid stimulation.

However, the WC-II did synthesize significantly

higher amounts of 6-keto-PGF 1 a upon stimulation by
arachidonic acid (WC-II- X = 13.40, Sx = 4.49; RBWC-

X = 5.43, Sx = 2.17), F = 10.19, p = 0.018.
Testing the correlation of the production of
the 6-keto-PGF 1 a to the production of TXB 2 using the
Pearson r correlation coefficient, showed a strong
co~relation (r

= 0.643, df = 7, p = 0.1) for the aorta

Age
(months)

RBWC

WC-II

Table 4.

TXB 2 Without A.A.
Stimulation (pg/10 8 )

TXB 2 With A.A.
Stimulation (pg/10 8 )

12

7.65

12.94

17

5.00

24.21

12

3.23

8.82

9

5.33

11. 33

18

47.92

58.33

19

18.82

17.06

10

5.20

164.00

9

6.25

25.63

Platelet rich plasma levels of TXB2 of the random bred White Garneau
(RBWC) and the White Garneau-II (WC-II), with and without· arachidonic
acig (A.A.) stimulation, expressed in picograms per 10 8 platelets.
[(RBWC - without A.A. - X = 5.3, Sx = 1.8; WC-II - without A.A. X = 19.5, Sx = 19.9), (RBWC - with A.A. - X = 14.32, Sx = 6.8;
WC-II - with A.A. - X = 66.25, Sx = 67.54)].

RBWC

WC-II

Table 5.

Age
(months)

6-keto-PGF 1 a Without A.A.
Stimulation (pg/mg)

6-keto-PGF 1 a With A.A.
Stimulation (pg/mg)

12

5.69

8.06

17

5.71

4.00

12

2.89

3.33

9

8.46

6.33

18

4.48

9.09

19

15.26

16.66

10

6. 43

17.86

9

7.11

10.00

Aorta ring levels of 6-keto-PGF 1 a of the random bred White Garneau
(RBWC) and the White Garneau-II (WC-II), with and without arachidonic
acid (A.A.) stimulation, expressed in picograms per mg (wet weight).
[(RBWC - without A.A. - X = 5.687, S-X = 2.27; WC-II - without A.A. X = 8.32, Sx = 4.75), (RBWC - with A.A. - X .= 5.43, Sx = 2.17;
WC-II - with A.A. - X = 13.40, S-X = 4.49)].
w

Ln
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rings stimulated with arachidonic acid to the stimulated
PRP for all the pigeons tested.

In addition, the

plasma levels of 6-keto-PGF 1 a and TXB 2 for all cases
showed a significant correlation (r = 0.796, df = 7,
p = 0.05).

Therefore, as the amount of TXB 2 increased
in the pigeons, so did the amount of 6-keto-PGF 1 a.
In order to test whether there were any differ-

ences in the ability of each strain to synthesize PGI

2

in response to TXA2 , the mean ratios of 6-keto-PGF a/
1
TXB 2 were analyzed between strains using the ANOVA at
the 0.05 level of significance.

Analysis for all

samples showed no significant differences.
Finally, to determine the relationship of
arachidonic acid to the susceptibility of atherosclerosis, the ratios of 6-keto-PGF a/TXB with and
1
2
without arachidonic acid stimulation were examined
within rather than between the two strains of the
White Carneau pigeon.

The mean ratio of 6-keto-PGF 1 a
to TXB 2 without stimulation for the RBWC was 1.075 with
S;; = 0. 386, and with stimulation, X = 0.45, S-X = 0.19.

Using the ANOVA, the mean ratio without stimulation
was found to be significantly higher (F = 8.408, p =
0.05), than the mean ratio with stimulation.

The

mean ratios for the WC-II without (X = 0.8, S-X = 0.496)
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-

and with arachidonic acid (X = 0.4,

Sx

= 0.403) were

not statistically different at the 0.05 level.

DISCUSSION
Although the White Carneau pigeon has been
widely used in the study of atherosclerosis, little
has been published about the super susceptible WC-II.
Therefore, this investigation is important as well as
interesting because of the more pronounced characteristics exhibited by the WC-II.
The platelet count showed no evidence of
differences in platelet number among the pigeons, and
since PGI

has been shown not to-influence the platelet
2
count (Gryglewski, 1980), it may be concluded that the

differences observed in the measured levels of TXB 2
reflect true differences in the amounts of TXA 2
generated by the platelets.
Even though the plasma levels of PGI

and TXA 2
2
were inconclusive of differences in the two strains,
it is important to remember that the level of PGI 2
was significantly correlated to TXA 2 . So as the level
of one increased, so did the other in a near one-to-one
relation.

Therefore, whatever the source or cause of

the increasing levels of TXA 2 in pigeons, it stimulated an increased production of PGI 2 .
Adding to these observations, it is evident
that the platelets of the super susceptible WC-II,
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even without arachidonic acid stimulation, were able
to synthesize a significantly higher amount of TXA2
in the three minute incubation period than the platelets of the RBWC.

This would indicate that whatever

the trigger mechanism, the platelets of the super
susceptible pigeons have a highly active enzyme system
producing larger amounts of TXA 2 than the platelets
of the less susceptible pigeons. It seems reasonable
',

to assume that this mechanism must be directly involved
with the more pronounced susceptibility to atherosclerosis of the WC-II.
When analyzing the response of the aorta
tissue, it is interesting to note that the greater
ability to utilize arachidonic acid to form PGI 2 is
not found in the less susceptible RBWC as would be
expected, but rather in the super susceptible WC-II.
This is the converse of what has been observed in
mammals.

In all RBWC and·WC-II tested, the synthetic

ability of the aorta to form PGI 2 increased as the
ability of the platelets to form TXA 2 increased.
Examining the ratio differences of the 6-ketoPGF1a/TXB2, with and without arachidonic acid stimulation for both strains, it appears that the significantly higher ratio of the RBWC without/with stimu-
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lation is indicative of this strain's ability to more
effectively produce PGI 2 in response to TXA . Even
2
with a decreased substrate, the RBWC was able to
produce larger amounts of PGI 2 in response to TXA
2
than the WC- II.
This would lead to the conclusion that the
RBWC is the less. susceptible strain, in part, because
of its ability to maintain higher levels of PGI

with
2
or without additional arachidonic acid availability

in response to TXA2 production. Even though the WC-II
shows an increased production of PGI when given
2
arachidonic acid stimulation, it does not have the
ability to maintain adequate PGI 2 levels against the
increased TXA2 .
It was shown by Young and Middleton (J966)
that the atherosclerosis resistant Show Racer male
pigeons had significantly higher percentage of
arachidonic acid of the serum sterol esters than the
White Garneau male, and that the Show Racer females
had a significantly higher percentage of arachidonic
acid of the liver sterol esters than the White Garneau
female pigeons.
This leads to the conjecture that the super
susceptible WC-II may lack available arachidonic acid
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in the aortic tissue examined, thus contributing to
its inability to maintain adequate PGI 2 levels.
This coupled to the greater ability of the
platelets of the WC-II to synthesize TXA 2 without
stimulation, reflecting in vivo conditions, adds to the
differences in the susceptibility of the two strains.
Therefore, the crit_ical balance between PGI 2
and TXA plays an instrumental role in the difference
2
in susceptibility of these two strains of the White
Garneau pigeon.
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